First Time Loading...

Lyra Therapeutics Inc
NASDAQ:LYRA

Watchlist Manager
Lyra Therapeutics Inc Logo
Lyra Therapeutics Inc
NASDAQ:LYRA
Watchlist
Price: 4.72 USD -8.7% Market Closed
Updated: Apr 29, 2024
Section:
 

Relative Value

The Relative Value of one LYRA stock under the Base Case scenario is 1.61 USD. Compared to the current market price of 4.72 USD, Lyra Therapeutics Inc is Overvalued by 66%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

LYRA Relative Value
Base Case
1.61 USD
Overvaluation 66%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

173.3
P/S
P/S
Price to Sales
173.3
vs History
18
vs Industry
2
Median 3Y
102.8
Median 5Y
73.4
Industry
2.4
Forward
191.9
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-2.8
Median 5Y
-3.2
Industry
22.9
Forward
-4.4
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-3.5
Median 5Y
-4.2
Industry
17.1
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-3.4
Median 5Y
-4
Industry
23.2
More Details
3
P/B
P/B
Price to Book Value
3
vs History
14
vs Industry
23
Median 3Y
1.8
Median 5Y
1.9
Industry
2.1
More Details
107.4
EV/S
EV/S
Enterprise Value to Sales
107.4
vs History
12
vs Industry
3
Median 3Y
37.9
Median 5Y
24.3
Industry
2.6
Forward
118.9
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.1
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
56
Median 3Y
-0.9
Median 5Y
-1.2
Industry
13.6
Forward
-2.8
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
53
Median 3Y
-0.9
Median 5Y
-1.2
Industry
17
Forward
-2.3
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
54
Median 3Y
-1.3
Median 5Y
-1.6
Industry
15.8
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
40
Median 3Y
-1.2
Median 5Y
-1.5
Industry
17.6
More Details
4.6
EV/IC
EV/IC
Enterprise Value to IC
4.6
vs History
63
vs Industry
17
Median 3Y
5.4
Median 5Y
6.2
Industry
1.9
More Details

Multiples Across Competitors

LYRA Competitors Multiples
Lyra Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Lyra Therapeutics Inc
NASDAQ:LYRA
270.1m USD 173.3 -4.3 -2.6 -2.6
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
696.4B USD 20.4 132.9 60.1 68.9
DK
Novo Nordisk A/S
CSE:NOVO B
3.9T DKK 17 47.1 34.3 37.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
JP
Taisho Pharmaceutical Holdings Co Ltd
TSE:4581
82T JPY 255.8 9 733.7 1 771.8 4 320.3
US
Johnson & Johnson
NYSE:JNJ
351.8B USD 4.3 8.7 11.6 15.3
US
Merck & Co Inc
NYSE:MRK
332.2B USD 5.5 910 45.2 88.2
UK
AstraZeneca PLC
LSE:AZN
188.6B GBP 5.1 39.6 140.7 225.8
CH
Novartis AG
SIX:NOVN
182.9B CHF 4.3 13.5 9.9 16.3
CH
Roche Holding AG
SIX:ROG
177.8B CHF 3 15.5 8.8 10.4
P/E Multiple
Earnings Growth
US
Lyra Therapeutics Inc
NASDAQ:LYRA
Average P/E: 1 362.6
Negative Multiple: -4.3 		N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
132.9
346%
DK
Novo Nordisk A/S
CSE:NOVO B
47.1
84%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
JP
Taisho Pharmaceutical Holdings Co Ltd
TSE:4581
9 733.7
-24%
US
Johnson & Johnson
NYSE:JNJ
8.7
-20%
US
Merck & Co Inc
NYSE:MRK
910
7 454%
UK
AstraZeneca PLC
LSE:AZN
39.6
168%
CH
Novartis AG
SIX:NOVN
13.5
15%
CH
Roche Holding AG
SIX:ROG
15.5
26%

See Also

Summary
LYRA intrinsic value, competitors valuation, and company profile.
DCF Valuation
LYRA stock valuation using Discount Cash Flow valuation method.
Relative Valuation
LYRA stock valuation using valuation multiples.
Wall Street Estimates
LYRA price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
LYRA stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 132,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.